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Abstract
Purpose: We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using
iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution.
Material and methods: Between April 2006 and December 2010, 169 men with early stage prostate cancer were
treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related
morbidities, including urinary, rectal and sexual function, were measured, applying the International Prostate
Symptom Score (IPSS), the 7-grade Quality of Life Scale (QoL) and medical status, the International Consultation on
Incontinence Modular Questionnaire (ICIQ), the International Index of Erectile Function (IIEF-5) and the Common
Terminology Criteria for Adverse Events (CTCAE v4.03). Seed migration and loss, dosimetric parameters and learning
effects were also analyzed.
Results: Medium follow-up time was 50 months (range, 1–85 months). The five-year biochemical failure rate was
7%. Acute proctitis rates were 19% (grade 1) and 1% (grade 2), respectively. The overall incidence of incontinence
was 19% (mild), 16% (moderate) and < 1% (severe). An increase in IPSS ≥ 5 points was detected in 59% of patients,
with 38% regaining their baseline. Seed dislocation was found in 24% of patients and correlated with D90 and
V100. A learning curve was found for seed migration, D90 and V100. QoL correlated with the general health
condition of patient, incontinence symptoms and IPSS.
Conclusions: BT for early stage prostate cancer offers excellent five-year biochemical control with low toxicities.
QoL aspects are favorable. A learning curve was detected for procedural aspects but its impact on patient relevant
endpoints remains inconclusive.
Keywords: LDR brachytherapy, Dosimetry, Quality of life, Toxicity, Biochemical failure, Learning curve
Introduction
Prostate cancer is the most common malignancy in men
in the developed world [1]. In Germany, the annual
incidence is estimated to be as high as 48,650 new
cases, accounting for approximately 22% of all cancer
in males [2].
Iodine-125 low dose rate brachytherapy (BT) is an
effective modality to administer a high dose to the pros-
tate while minimizing toxicities for the adjacent organs
at risk [3]. For selected patients with low and favorable
intermediate-risk prostate cancer, BT is equally effective
in controlling the disease as radical prostatectomy [4].
For men who place a premium on avoiding side effects
of treatment and who accept the possible risk of late me-
tastasis or death, also lack of treatment with an active
surveillance strategy can be appropriate [5].
Judging the quality of an implant by dosimetric param-
eters is recommended by the American Brachytherapy
Society (ABS) [6] and the European Society for Radio-
therapy & Oncology, European Association of Urology
and European Organization for Research and Treatment
of Cancer (ESTRO/EAU/EORTC) [7]. Dose homogeneity
within the target volume is much more difficult to
achieve during BT than during external beam radiothe-
rapy (EBRT), and implants are rarely geometrically per-
fect. To avoid partial underdosage of the target volume,
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it may be necessary to accept hot spots in other parts of
the target volumes, but it is not clear how much dose
heterogeneity should be considered excessive [8].
A known phenomenon after BT is the detachment of
seeds from their initial site and migration to other or-
gans. Seed migration may be identified in up to 55 per-
cent of patients who are monitored with routine chest
x-rays [9]. Also dislocation within the abdomen or pelvis
is observed, with the majority of patients being asymp-
tomatic [10]. Only very few migration-related sequelae
have been reported, such as cases of myocardial infarc-
tion and radiation pneumonitis [11,12].
It stands to reason that quality of life (QoL) can be in-
fluenced by the adverse effects of BT. Typically, these
are expressed in the gastrointestinal and genitourinary
tract system. Toxicities after BT that have been reported
are challenging to compare due to differences in follow-
up time, disease profile at presentation, study endpoints
and treatment regimens, which differ from a permanent
implant alone to the combination with EBRT and/or an-
drogen ablation [13]. According to the literature, urinary
retention occurred in 5-22% of the patients after seed
implantation alone [14,15]. Acute urinary symptoms in-
creased by over 100% in patients treated either with BT
alone or BT combined with EBRT. However, most stu-
dies found that about 90% of patients will have norma-
lized their urinary complaints by one year postimplant
[16,17]. Urinary incontinence after BT (without associ-
ated transurethral resection of the prostate) is reported
in 0-19% of patients [18,19]. The incidence of radiation
proctitis following implantation ranges from 1-19% in
patients treated with implants alone [20,21]. Poor sexual
function is reported in 43-48% of patients [22].
Several retrospective studies demonstrated the impact
of implantation experience on the quality of the pro-
cedure: Lefur et al. [23], observed a learning curve to
achieve consistent implantation parameters, which lead
to a significant decrease in the dose to the rectum. They
found no impact on the dosimetric parameters for the
target volume, however. On the contrary, Hong-Wie Liu
et al. [24] reported steadily decreasing numbers of pa-
tients with low D90s as their implant program matured.
Keyes et al. [25] showed significantly falling acute
urinary retention rates by order of implants. A learning
curve could also be seen avoiding seed migration [26].
The aim of this study is to report our single-institution
experience with BT for patients diagnosed with early-
stage prostate cancer, highlight treatment related toxi-
cities and analyze their relation to QoL.
Patients and methods
All 169 men who were diagnosed with localized low-
and intermediate risk prostate cancer and treated with
BT as a monotherapy between April 2006 and December
2010 were enrolled in this retrospective study. Patient
characteristics are shown in Table 1. No patients were
excluded. BT was indicated according to above men-
tioned guidelines; intermediate-risk patients were con-
sidered for brachytherapy on a case-by-case basis.
Monotherapy was used judiciously at the discretion of
the treating physicians and upon the patients’ prefe-
rences. Median age and PSA value at diagnosis were
68.5 years (range: 47–79) and 7.2 ng/mL (range: 0.14-
14.88), respectively. The majority of patients (91.8%) had
a Gleason score of six (range: four to seven), while 1.2%
had a Gleason score of seven. Treatment outcome was
assessed using the Common Terminology Criteria for
Adverse Events (CTCAE v4.03) for proctitis, the inter-
national prostate symptom score (IPSS) [27] and a ques-
tionnaire for prostate cancer patients developed by the
German Cancer Society (DKG). Included in this ques-
tionnaire is the self-evaluation of QoL and medical con-
dition using scales from zero to seven. These correspond
to items used in validated questionnaires of the EORTC
Table 1 Patients’ characteristics
Age (year)
Mean ± SD 68.5 ± 5.6
PSA at diagnosis (ng/mL)
Mean ± SD 7.2 ± 2.6
10 or less 144
10-20 25
Clinical T stage
T1c 143
T2a 16
T2b 7
T2c 1
Ne 2
Gleason score
4-6 166
7 2
Ne 1
Neoadjuvant ADT
No 125
Yes 42
Ne 2
IPSS at baseline
Mean ± SD 6.3 ± 4.0 (*)
Follow-up period (months)
Mean (range) 50 (1–85 months)
SD: Standard deviation, Ne: Not evaluated.
ADT: Androgen deprivation therapy.
IPSS: International prostate symptom score.
(*) 162 patients included.
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[28]. Further items are questions about urinary and rec-
tal continence according to the international consult-
ation on incontinence modular questionnaire (ICIQ)
[29] and the abbreviated five-item version of the inter-
national index of erectile function (IIEF-5) [30]. Patients
had a follow-up on a regular basis, four to six weeks,
then three, six, 12, 18, 24 and 36 months post im-
plantation. The medium follow-up time was 50 months
(range: 1–85). All patients gave their informed consent
regarding the use of their records for this study. The
Klinikum Chemnitz data security officer approved the
study.
Treatments were performed with 125-Iodine seed BT
by two experienced urologists using a Mick applicator.
160 Gy to the prostate was prescribed. Collected data in-
cluded the prostatic volume, D90 (isodose enclosing 90%
of the prostate in Gy and percent), V100 of the prostate
(percentage volume of the target receiving 100% of the
prescribed dose), rectal V100 (volume receiving 100% of
the prescription dose) at implantation and after treat-
ment, and urethral D30 (isodose enclosing 30% of the
urethra), at implantation only. The dosimetric para-
meters are summarized in Table 2. We aimed for a
V100 ≥ 95%, urethral D30 < 130%, and a rectal V100 < 1 cc
(evaluated for 145 Gy). For orientation, values of V90.6
(equals volume receiving 145 Gy) were additionally re-
corded. Despite existing target values, patients whose pa-
rameters did not reach those at post-implant assessment
did not receive any further treatment. Forty-two patients
(24.4%) received neoadjuvant androgen deprivation ther-
apy (NADT). Short-term anti-hormonal treatment was
used for the purpose of prostate down sizing before
brachytherapy and was based on implanting surgeons’
individual decisions. No threshold was defined. CT-based
postimplant dosimetry was routinely performed 4–6
weeks after BT for all patients.
Data collection, management, analysis and visuali-
zation were performed with Microsoft Office Profes-
sional 2007 and IBM SPSS Statistics for Macintosh,
Version 22.0. Armonk, NY: IBM Corp. P-values below
0.05 were considered statistically significant.
In order to reach a higher data quantity for a valid in-
terpretation, an additional written survey was conducted.
Of all patients, 111 returned completed questionnaires.
Self-estimated QoL was correlated with health status,
ICIQ, IIEF-5, IPSS and GI toxicity using Spearman’s rho.
Moreover, all potentially influencing dosimetric and pre-
therapeutic parameters were correlated with these out-
come variables, e.g. the urethral D30, volume of the
prostate and pre-therapeutic IPSS with ICIQ scores or,
the rectal V100 and volume of the prostate with GI
toxicity. The strength of correlation was interpreted as
weak for ρ < 0.5, moderate for 0.5 ≤ ρ < 0.8 and strong
for ρ > 0.8. As for interpretation of the IPSS, we followed
the definition of an absolute rise in score of five points
to represent clinically significant worsening in the pa-
tients’ urinary symptoms, as initially used and validated
by Cesaretti et al. [31].
To determine whether there were differences between
the implant qualities of the two surgeons, an unpaired
t-test was employed. The tested variables are metric and
the sample size is large enough. According to the central
limit theorem, it can thus be employed without tests on
normal distribution. To assess the equality of variances
for all variables calculated for the two groups, Levene’s
test was used.
Table 2 Dosimetric parameters
No. of pts. Mean ± SD Min Max
Urethra D30 [Gy] at implantation (1) 167 185.5 ± 6.7 159.8 204.5
Prostate V [cc] at implantation (2) 150 31.9 ± 11.3 12.8 63.0
Prostate V [cc] postimplant (2) 163 31.8 ± 11.1 13.8 61.4
Prostate D90 [Gy] at implantation (3) 167 185.5 ± 4.0 173.7 198.4
Prostate D90 [Gy] postimplant (3) 165 179.2 ± 16.3 118.6 210.6
Prostate V100 [%] at implantation (4) 167 99.6 ± 0.5 97.5 100
Prostate V100 [%] postimplant (4) 165 94.9 ± 3.8 80.7 100
Prostate V90.6 [%] at implantation (5) 167 99.9 ± 0.2 98.4 100
Prostate V90.6 [%] postimplant (5) 165 97.0 ± 3.8 64.5 100
Rectum V100 [cc] at implantation (6) 167 0.3 ± 0.2 0 1.2
Rectum V100 [cc] postimplant (6) 165 0.5 ± 0.6 0 3.2
(1) dose to 30% of the urethra.
(2) volume of the prostate.
(3) dose to 90% of the prostate.
(4) percentage volume receiving 100% of the prescription dose.
(5) percentage volume receiving 90.6% of the prescription dose.
(6) volume of the rectum receiving 100% of the prescription dose.
Zuber et al. Radiation Oncology  (2015) 10:49 Page 3 of 10
To investigate a possible pattern of learning effects,
the study population was divided into a group of 85
patients (early implantations) and 84 patients (late im-
plantations), respectively. As depicted above, Levene’s
and unpaired t-tests could be used for comparison. In-
cluded variables were the number of lost or dislocated
seeds and the above-mentioned dosimetric parameters.
Data were also evaluated separately for both surgeons.
Results
The incidence of proctitis at different time points after
BT is displayed in Figure 1. The number of patients
available for analysis is provided in brackets. No grade
three or higher events were reported.
For 105 men, grading of proctitis at 1.5 months after
treatment was obtained, and at least another data point
during further follow-up. Of these patients, 21% (n = 22)
showed improvement of proctitis symptoms in follow-
up. As many as 9.5% (n = 10) experienced worsening of
associated complaints (nine patients with grade one and
one patient with grade two morbidity).
The IPS-scoring system allows urinary symptoms to be
classified as mild (IPSS 0–7), moderate (IPSS 8–19), or se-
vere (IPSS ≥ 20). Included in this subanalysis were 118 pa-
tients who completed the IPSS questionnaire before BT, at
first follow-up (1.5 months) and at least one more time
between three months and three years post implantation.
Figure 2 displays the prevalence of symptoms at different
points in time after BT. Table 3 shows the number of
patients evaluated with an increase of more than five
points in post treatment IPSS at 1.5 months, and a de-
crease of ≥ 5 beyond 1.5 months, respectively.
A total of 135 patients completed at least one DKG
questionnaire. Six patients completed all subcategories
except the IIEF-5. Forty-three patients completed one,
81 patients two and 11 patients three questionnaires.
When more than one questionnaire per patient was ob-
tained, the worst and best results within the follow-up
period were utilized. The results of this self-estimation
and distribution after BT are illustrated in Figures 3a-d.
The 7-item scales for QoL and medical condition were
construed as follows: 1 very discontent, 2 discontent, 3
rather discontent, 4 neither/nor, 5 rather content, 6 con-
tent, 7 very content.
Biochemical failure was defined as a rise of two ng/mL
or more above nadir, and based on the RTOG-ASTRO
Phoenix Definition [32]. For calculation of the five-year
biochemical free-survival, 59 patients with a follow-up of
at least 60 months or prior recurrent disease were in-
cluded. One pretreatment and at least two PSA values
after BT were available. Table 4 shows the further
details. Four patients (7%) showed PSA failure in accor-
dance with the RTOG-ASTRO Phoenix definition, oc-
curring at 42, 48, 54, and 63 months, respectively.
Figure 4 shows the Kaplan-Meier estimates.
For a total of 164 patients, we were able to investigate
the pattern of seed migration or loss. Most patients,
n = 127 (75.6%), did not experience seed loss. The dis-
location of a single seed was observed in 29 (17.7%) pa-
tients. Two seeds were lost in eight (4.9%), three in two
(1.2%), and four in one of the patients. Predominant
sites of migration/dislocation were to seminal vesicles,
periprostatic tissues and lungs, occurring in 27, 13, and
10 patients, respectively. For one patient, a single seed
Figure 1 Proctitis grading according to CTCAE v.4.03 (grade 0: no symptoms).
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that was lost could not be identified. Another patient
lost a seed during urination. Furthermore, single seed
embolization into the spinal canal, presacral space, and a
deferent duct was observed in three patients (one patient
for each site).
Almost all QoL-related aspects (7-grade scales and
genitourinary symptoms) that were obtained by ques-
tionnaires or upon consultation within the observation
period showed a positive correlation at different points
in time, except for proctitis. To determine the asso-
ciation of these aspects, pre-implant and dosimetric pa-
rameters, the last retrieved questionnaires were used.
Dependent variables are shown in Table 5. Represented
are those correlation coefficients where statistical signifi-
cance was given.
Discussion
Due to the similar size of the referral base, many institu-
tions in Germany as well as in other European countries
offering BT have a comparable patient throughput. It is
still important that patient series from smaller depart-
ments are analyzed to increase the quantity of comparable
results, particularly since there are no randomized
controlled studies to date that would permit an evidence-
based assessment of the benefit of BT over other treat-
ment options. In Germany, directives for the benefit
catalogue of the statutory health insurance funds are
issued by the G-BA (Federal Joint Board): Accordingly,
there is no evidence regarding the patient-relevant
endpoints, such as overall survival and diseases specific
mortality. However, it has been stated that there is “some”
evidence in terms of treatment toxicity: Rectal function
may be more impaired when compared to EBRT, while
sexual dysfunction and urinary incontinence may be less
when compared to prostatectomy [33]. A decision process
regarding general coverage of BT has been suspended,
providing that higher evidence by adequate studies is
achieved. During the method evaluation process, BT is
normally only funded by statutory insurances in a hospital
setting. Exploitable results of larger prospective rando-
mized trials, such as the German prostatic cancer study
PREFERE [34], are expected.
Overall disease free survival at five years in patients
after BT differ between 76-93% [35-37]. As with toxicity,
the series with BT as a monotherapy are difficult to
compare due to differences in the follow-up time and
treatment regimens. Furthermore, divergent definitions
for biochemical failure were chosen. In this study, the
rate of biochemical failure according to the RTOG-
ASTRO Phoenix Definition [32] was low. The five-year
biochemical recurrence-free survival was 93% for pa-
tients with a follow up of at least 60 months or prior re-
current disease. The actual rate may be even higher.
Many patients had low PSA-values upon follow-up but
could not be included in the subgroup analysis, due to
lacking further values. Despite the relatively small num-
ber of patients included, our results are encouraging and
in line with results from above cited studies.
Figures 1, 2, 3 demonstrate a good outcome in our
study population in terms of aspects related to QoL,
except for sexual dysfunction. Voiding symptoms de-
creased over time. There was also a low rate of proctitis
according to toxicity grading, and the majority of
patients had no signs of urinary incontinence. Most
patients stated being rather content, content or very
content with QoL. Self-appraisal of QoL was associated
most strongly with that of general health condition
Figure 2 Voiding symptoms according to International Prostate Symptom Score.
Table 3 Post-treatment changes in IPSS
No. of pts. (%) IPSS (mean ± SD)
Included patients 118 (100%) 11.2 ± 5.1
≥ 5-point increase at 1.5 months 70 (59%) 6.8 ± 3,3
≥ 5-point decrease after
1.5 months
45 (38%) 4.6 ± 2.1
IPSS: International prostate symptom score, SD: Standard deviation.
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(ρ = 0.8) and weakly correlated with the ICIQ (ρ = −0.21)
and IPSS (ρ = −0,20). There was no significant correlation
between QoL, the rate of proctitis or the IIEF-5 score.
From experience, one of the reasons men seek im-
plantation over surgery when considering their treat-
ment options for early-stage prostate cancer is the
a)
b)
c)
d)
Figure 3 Treatment outcome. a. Quality of Life (7-grade scale). b. Medical condition (7-grade scale). c. Incontinence symptoms according to
International Consultation on Incontinence Questionnaire. d. Sexual dysfunction according to International Index of Erectile Function (5-item version).
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potentially lower risk for ED. In this study, ED was
assessed with the IIEF-5. ED was not associated with
worsening of QoL. Explanations for this finding might
include a declining sexual interest with age (mean:
68.5 years in this study) or acceptance of sexual dysfunc-
tion over time. Furthermore, the IIEF was not designed
to assess the impact of ED on psychosocial outcomes
that influence sexual function. In fact, it was developed
primarily for use as an efficacy measure in clinical trials
of ED [38]. Its 5-item version is a simple office screening
instrument to diagnose the presence and severity, with a
focus only on erectile function and intercourse satis-
faction [30]. Moreover, male sexual dysfunction includes
diminished libido or abnormal ejaculation, issues that
are not addressed in the questionnaire. Various con-
ditions are known to be associated with ED, such as
cardiovascular disease, obesity, diabetes mellitus, certain
drugs, or depression [39]. In this study, patients with co-
morbidities were not excluded. Though representative
for the general population, our data would not allow to
clearly attribute the pattern of ED to BT.
Due to the anatomic proximity of the prostate to the
urethra and bladder, both acute and late toxicity can be
observed. Most patients develop an acute worsening of
urinary symptoms, such as increased frequency, urgency,
nocturia, etc. These symptoms resolve in most cases
[40]. We assessed urinary symptoms using the IPSS and
observed an increase of ≥ five points in 59% of the pa-
tients, approximately six weeks post implant. Of these,
38% reached their baseline level. In a study by Keyes
et al., similar results were found in 712 men with loca-
lized prostate cancer treated with an I-125 implant bet-
ween 1998 and 2003 [40]: By six weeks after treatment,
most patients experienced an acute exacerbation of urin-
ary symptoms, which was associated with an increase in
the IPSS to a mean of approximately 19. Symptoms re-
solved within six months in 65% of cases and within one
year in 91%. Associated factors included more baseline
urinary symptoms and more intense symptoms in the
immediate post-treatment period. In our patients, there
was a weak correlation between the last retrieved IPSS
and the pretherapeutic scores. Neither the size of the
Table 4 PSA course
PSA Evaluable pts. Pts. with
PSA failure
Pts. with a
follow-up
more than
60 months
No. of pts. (%) 141 6 (4.3%) 55 (39.0%)
Pretreatment PSA 7.1 ± 2.5 6.3 ± 1.5 7.0 ± 2.5
PSA Nadir 0.4 ± 0.6 1.3 ± 1.6 0.1 ± 0.2
SD: Standard deviation.
Figure 4 Kaplan-Meier estimates.
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prostate nor the urethral D30 impacted the IPSS. Serious
rectal injuries (fistula) are rare [41] and were not observed
in our study. An accurate implant technique can minimize
the radiation dose to the anterior rectal wall and
brachytherapy-related bowel morbidity. This was shown,
for instance, by Snyder et al. [42], who demonstrated a
correlation between the V100 and the development of
grade 2 proctitis: If ≤ 0.8 cc of rectal wall received 160 Gy,
no proctitis developed. The likelihood increased to 5% in
case ≤ 1.3 cc received 160 Gy. In our study, the incidence
of proctitis complaints was low. There was no significant
association with QoL and the incidence was not influ-
enced by rectal dosimetric parameters.
After BT, loose seeds are particularly prone to loss and
movement. The loss of multiple seeds can cause a sub-
stantial reduction of D90 coverage. Stranded seeds are less
prone to be lost [43]. A weak but statistically significant
correlation between the number of lost seeds and dosi-
metric parameters (V100, D90) could also be shown in
this study. The clinical implications of this are unclear. A
prescription dose of 160 Gy to the prostate used to be the
local standard during the first years of implantations, lean-
ing upon a dose–response analysis by Stock et al. [44]:
They recommended a range of 140–160 Gy delivered to
the prostate as defined by the D90. In practice however,
many brachytherapists plan a higher dose [6] to compen-
sate for edema or seed placement uncertainty and D90s
from 180 to 200 Gy seem to be well tolerated with low
risk of toxicity [45]. As for the urethra, one may aim for
an UV30 < 125% [6] or a D30 < 130% of the prescription
dose when referred to GEC-ESTRO recommendations [7].
At the rectum, the RV100 is ideally < 1 cc at day 1 dosi-
metry and < 1.3 cc at day 30 (due to the resolution of peri-
prostatic edema and, thus, changing proximity) [6].
A thorough evaluation of differences between day 0
and post-implant dosimetry was beyond the scope of this
work. Prostate edema after BT is well recognized and
can result in a decrease in dose coverage [46]. The ex-
tent and time course of prostate edema and its effect on
dosimetry have been analyzed for example by Taussky
et al. [46] In this study, we compared the dosimetric re-
sults of two experienced surgeons. Our analyses indicate
a significant difference between the surgeons for urethral
D30. However, both reached values within recom-
mended constraints. For other planning parameters, for
neither seed loss nor dislocation, no significant diffe-
rences were found. Moreover, we looked at two different
time periods to evaluate possible learning effects as de-
scribed in the literature. Our observation of a learning
curve for variables defining the quality of an implant-
ation partially corroborates effects that were previously
noted: Within our chosen observation periods, signifi-
cant changes were demonstrated: Less seeds were lost or
dislocated and values of V100 and D90 increased over
time. A closer examination performed separately for the
implanting physicians reveals a slightly different picture.
Both surgeons reached a significantly improved rate of
seed loss over time, whereas a significant increase of
V100 was only observed for one. Despite these effects,
the clinical relevance remains unknown. In terms of
tumor control probability, the D90 is particularly im-
portant [44]. Moreover, the V100 could be a good
clinical indicator for a successful implant. As for D90,
obtained values for the early 85 implants was 174.6 Gy
and, 184.0 Gy for the succeeding 84 implants: again,
both meeting the recommendations. Recording all pa-
rameters separately for different implantation teams
served as an additional means of quality control. Though
statistically significant, the differences of the implant
quality were minor. As a matter of fact, a higher learning
capacity or better manual skills could not be derived
from our data. In most prostate LDR brachytherapy pro-
grams, it is seen that the implant quality increases with
the number of procedures performed up to about 70 to
100 procedures [47,48]. However, technological advances
have taken place and made the implantation procedure
more precise [48].
Conclusion
BT constitutes one of many effective and safe treatment
options for early-stage prostate cancer. The five-year
biochemical relapse-free survival is excellent and treat-
ment toxicity is favorable. However, treatment-related
side effects, even when mild, have to be discussed with
the patient. Quality of life and its related aspects are
generally good. Learning effects by number of implants
occur, but their impact on patient-relevant endpoints is
inconclusive from our data.
Table 5 Significant correlations
No. of pts. Spearmen-Rho p-value
Quality of life
Health status 111 0.882 0.000
ICIQ (1) 111 −0.211 0.027
IPSS (2) 104 −0.204 0.037
Urethral D30 (3)
Volume of prostate 162 −0.326 0.000
IPSS at survey
IPSS (preimplant) 103 0.287 0.003
Seed dislocation/loss
V100 (4) 163 −0.262 0.001
D90 (5) 163 −0.190 0.015
(1) ICIQ: international consultation on incontinence modular questionnaire.
(2) IPSS: international prostate symptom score.
(3) D30: dose to 30% of the urethra.
(4) V100: volume of the prostate receiving 100% of the prescription dose.
(5) D90: dose to 90% of the prostate.
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